0QAV Stock Overview
A clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nanobiotix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.99 |
| 52 Week High | €7.73 |
| 52 Week Low | €3.86 |
| Beta | 1.29 |
| 11 Month Change | -10.50% |
| 3 Month Change | -8.57% |
| 1 Year Change | -27.28% |
| 33 Year Change | -54.11% |
| 5 Year Change | -45.43% |
| Change since IPO | -85.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QAV | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.5% | -3.3% | 0.4% |
| 1Y | -27.3% | -17.7% | 7.6% |
Return vs Industry: 0QAV underperformed the UK Biotechs industry which returned -16.7% over the past year.
Return vs Market: 0QAV underperformed the UK Market which returned 8.7% over the past year.
Price Volatility
| 0QAV volatility | |
|---|---|
| 0QAV Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.9% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0QAV's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0QAV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 110 | Laurent Levy | www.nanobiotix.com |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. Fundamentals Summary
| 0QAV fundamental statistics | |
|---|---|
| Market cap | €186.30m |
| Earnings (TTM) | -€33.47m |
| Revenue (TTM) | €42.20m |
4.4x
P/S Ratio-5.6x
P/E RatioIs 0QAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QAV income statement (TTM) | |
|---|---|
| Revenue | €42.20m |
| Cost of Revenue | €0 |
| Gross Profit | €42.20m |
| Other Expenses | €75.68m |
| Earnings | -€33.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -79.31% |
| Debt/Equity Ratio | -204.3% |
How did 0QAV perform over the long term?
See historical performance and comparison